Hong Kong
· Delayed Price · Currency is HKD VISEN Pharmaceuticals Company Description
VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of endocrine therapies in the People’s Republic of China, Hong Kong, and Taiwan.
Its lead product, Lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency.
The company also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism.
It has strategic collaboration agreements with Shanghai Pharmaceutical and the United Family Healthcare.
The company was incorporated in 2018 and is headquartered in Suzhou, China.
| Country | Cayman Islands |
| Founded | 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | An-bang Lu |
Contact Details
Address: Building B, Hengtai Lixiang Chuangxin Tower Suzhou, 215000 China | |
| Website | visenpharma.com |
Stock Details
| Ticker Symbol | 2561 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG9474A1004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| An-bang Lu | Chief Executive Officer and Executive Director |
| Dr. Jun Chen Ph.D. | Chief Commercial Officer |
| Sze Ting Chan A.C.S. | Company Secretary |